Aurobindo Pharma subsidiary gets EIR from USFDA

22 Sep 2022 , 11:21 AM

The companys subsidiary received an EIR mentioning the inspection a voluntary action initiated (VAI) from the United States Food and Drug Administration (USFDA) and with this, the USFDA pre-approval inspection and good manufacturing practice (GMP) inspection are concluded, the company said. Aurobindo Pharma develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients. The pharmaceutical company reported 32.4% fall in consolidated net profit to Rs 520.5 crore in Q1 FY23 from Rs 770 crore in Q1 FY22. Revenue from operations increased 9.4% YoY to Rs 6,235.9 crore in Q1 FY23. Shares of Aurobindo Pharma were down 0.73% to Rs 521.30 on the BSE. Powered by Capital Market – Live News